Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD

Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
January 30, 2014

Selecting the Appropriate Test for Individual Patients and Tumors

In this next segment, Dr Agarwala discusses when and how molecular tests should be utilized.

October 8, 2014

Approaching Unmet Clinical Needs in Polycythemia Vera

Dr. Michaelis discusses what approaches she takes for PV patients with unmet clinical needs such as recurrent thrombosis or hemorrhage. Supported through funding from Incyte